Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR
TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated …

Abstract Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations,
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …

Background Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2
(HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC) …

Methods Patients with HER2-overexpressing metastatic NSCLC were treated with T-DXd 6.4
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …

Sensitivity to Her2-directed therapies is complex and involves expression not only of Her2
but also of other epidermal growth factor receptor (EGFR) family members, their ligands, and …

Background Tarloxotinib is a hypoxia-activated prodrug of a pan-ErbB kinase inhibitor that
releases a potent irreversible active metabolite (tarloxotinib-E) under hypoxic conditions to …

Purpose: HER2-targeted therapy is not standard of care for HER2-positive non–small cell
lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2 …

Background Treatment of non-small cell lung cancer (NSCLC) with EGFR or HER2 exon 20
mutations is a serious unmet medical need. We are evaluating the efficacy and safety of …

Objectives The selective RET-inhibitor pralsetinib has shown therapeutic activity in early
clinical trials in patients with non-small cell lung cancer (NSCLC) harboring rearranged …

• Pralsetinib is a well-tolerated once-daily oral treatment option for patients with RET fusion–
positive metastatic NSCLC, with a safety profile consistent with previous reports and no new …